Protocol

Gene Therapy of Solid Cancers

Volume 1317 of the series Methods in Molecular Biology pp 39-51

MIDGE Technology for the Production of a Fourfold Gene-Modified, Allogenic Cell-Based Vaccine for Cancer Therapy

  • Manuel SchmidtAffiliated withMologen AG Berlin Email author 
  • , Barbara VolzAffiliated withMologen AG
  • , Patrick GroßmannAffiliated withMologen AG
  • , Kerstin HeinrichAffiliated withMologen AG
  • , Burghardt WittigAffiliated withFoundation Institute Molecular Biology and Bioinformatics, Freie Universität Berlin Email author 

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Gene modification of eukaryotic cells by electroporation is a widely used method to express selected genes in a defined cell population for various purposes, like gene correction or production of therapeutics. Here, we describe the generation of a cell-based tumor vaccine via fourfold transient gene modification of a human renal cell carcinoma (RCC) cell line for high expression of CD80, CD154, GM-CSF, and IL-7 by use of MIDGE® vectors. The two co-stimulatory molecules CD80 and CD154 are expressed at the cell surface, whereas the two cytokines GM-CSF and IL-7 are secreted yielding cells with enhanced immunological properties. These fourfold gene-modified cells have been used as a cell-based tumor vaccine for the treatment of RCC.

Key words

Cell-based tumor vaccine MIDGE vector Non-viral vectors Electroporation Transient transfection